These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28251386)

  • 1. Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
    Muralidharan KK; Steiner D; Amarante D; Ho PR; Mikol D; Elkins J; Subramanyam M; Nestorov I
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):263-275. PubMed ID: 28251386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
    Melis M; Cocco E; Frau J; Lorefice L; Fenu G; Coghe G; Mura M; Marrosu MG
    Neurol Sci; 2014 Mar; 35(3):401-8. PubMed ID: 23990111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
    Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
    Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis.
    Muralidharan KK; Kuesters G; Plavina T; Subramanyam M; Mikol DD; Gopal S; Nestorov I
    J Clin Pharmacol; 2017 Aug; 57(8):1017-1030. PubMed ID: 28398628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
    Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis Patients.
    Puñet-Ortiz J; Hervás-García JV; Teniente-Serra A; Cano-Orgaz A; Mansilla MJ; Quirant-Sánchez B; Navarro-Barriuso J; Fernández-Sanmartín MA; Presas-Rodríguez S; Ramo-Tello C; Martínez-Cáceres EM
    Cytometry B Clin Cytom; 2018 Mar; 94(2):327-333. PubMed ID: 28378895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.
    Dalton CM; Miszkiel KA; Barker GJ; MacManus DG; Pepple TI; Panzara M; Yang M; Hulme A; O'Connor P; Miller DH
    J Neurol; 2004 Apr; 251(4):407-13. PubMed ID: 15083284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.
    O'Connor P; Miller D; Riester K; Yang M; Panzara M; Dalton C; Miszkiel K; Khan O; Rice G; Sheremata W;
    Mult Scler; 2005 Oct; 11(5):568-72. PubMed ID: 16193895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
    Castellazzi M; Delbue S; Elia F; Gastaldi M; Franciotta D; Rizzo R; Bellini T; Bergamaschi R; Granieri E; Fainardi E
    Dis Markers; 2015; 2015():901312. PubMed ID: 26101453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity.
    Bates D; Bartholomé E
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):55-60. PubMed ID: 21865211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
    Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
    Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended interval dosing of natalizumab in multiple sclerosis.
    Zhovtis Ryerson L; Frohman TC; Foley J; Kister I; Weinstock-Guttman B; Tornatore C; Pandey K; Donnelly S; Pawate S; Bomprezzi R; Smith D; Kolb C; Qureshi S; Okuda D; Kalina J; Rimler Z; Green R; Monson N; Hoyt T; Bradshaw M; Fallon J; Chamot E; Bucello M; Beh S; Cutter G; Major E; Herbert J; Frohman EM
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):885-9. PubMed ID: 26917698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.